SeqOnce BioSciences, Inc. is raising up to $1.24M on OpenDeal Portal LLC in safe (simple agreement for future equity) at $1 each; in its filing revenue was $2.59M and it had 11 employees (Form C-U, 2025-05-07).
SeqOnce BioSciences, Inc. filed a Regulation Crowdfunding offering with the SEC through OpenDeal Portal LLC, with a target of $50K and a maximum of $1.24M. As of November 6, 2026, the offering is past its deadline of April 30, 2025. The company gives its address as Carlsbad, CA (Form C, February 18, 2025).
Sell to companies like SeqOnce BioSciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
SeqOnce BioSciences, Inc., based in Carlsbad, CA, filed a Regulation Crowdfunding offering with the SEC, the latest on 2025-02-18, raising through OpenDeal Portal LLC. It set a target of $50K and will accept up to $1.24M. The security offered is safe (simple agreement for future equity) at $1 each. As of its filings the offering is past its deadline of 2025-04-30. 2 filings in this family are on record for the company.
Terms at a glance
| Target | $50K |
| Maximum it will accept | $1.24M |
| Security | SAFE (Simple Agreement for Future Equity) |
| Price per unit | $1 (set by the company) |
| Units at the target | 50,000 |
| Raise above the target | accepted, first-come, first-served basis |
| Deadline | 2025-04-30 |
| Raising through | OpenDeal Portal LLC |
| What the portal is paid, as filed | At the conclusion, Issuer shall pay the Intermediary the greater of: (A) (i) 0% of funds raised up to $100,000, and (ii) 6% of funds raised between $100,000.01 and $5,000,000; or (B) a $15,000 cash fee. Additionally, the Issuer paid a non-refundable $7500 |
Check before you invest in SeqOnce BioSciences, Inc.: who signed the filing and its own figures, free.
Free to see. No signup.
Want the whole picture on SeqOnce BioSciences, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on SeqOnce BioSciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on SeqOnce BioSciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
The filing does not state a company valuation or a minimum investment; the offering page on OpenDeal Portal LLC shows those. Check both before you invest.
Money raised before
Earlier raises by this company that are on file, with the amounts as filed. A figure for a raise is what the company reported, not a check of what it received.
| Filed | What | Amount as filed | Filing |
|---|---|---|---|
| 2024-11-05 | Private placement (Form D) | $882K sold of $882K offered | filing |
Offering filings
| Filed | Intermediary | Target | Maximum | Deadline | Security | Filing |
|---|---|---|---|---|---|---|
| 2025-02-18 | OpenDeal Portal LLC | $50K | $1.24M | 2025-04-30 | SAFE (Simple Agreement for Future Equity) | C |
Financials the company filed
Figures from the C-U filed 2025-05-07, as the company reported them.
| As filed | Most recent fiscal year | Prior fiscal year |
|---|---|---|
| Revenue | $2.59M | $16.66M |
| Net income | -$2.34M | -$1.53M |
| Total assets | $2.69M | $7.07M |
| Cash and equivalents | $255K | |
| Short-term debt | $1.50M | |
| Long-term debt | $0 |
Employees at filing: 11.
Revenue went from $16.66M to $2.59M (-84%). Net loss was $2.34M, against a loss of $1.53M the year before. It reported $255K in cash and $1.50M in debt. These are the company's own figures from the Form C-U filed 2025-05-07.
Progress updates
2025-05-07, C-U:
The Offering closed successfully on 5/1/2025, having received investment commitments of $117,516, although a final accounting has not taken place.
People who signed the filing
- Christopher Angermayer, Director
- Joseph Dunham, Director
Every filing
What to check before investing
- Read the offering page on OpenDeal Portal LLC: it states the valuation or cap and the minimum investment, which the SEC filing does not.
- Compare the terms above with the numbers: what does the price imply against revenue of $2.59M?
- Look at who signed the filing and what else they have run (the founder Snapshot below).
- Check the deadline and what happens if the target is missed.
- You cannot easily sell a crowdfunding security; invest only what you can leave tied up.
A crowdfunding round is won in public. FoxPlug turns your commits, deploys and releases into the posts and visuals that keep the story moving while the offering is open.
Build your launch kitRun a Snapshot on Christopher Angermayer: other companies, roles and the record behind them. Order Full Report from there if you need more.
Snapshot the foundersTools for this story
Each opens in a new tab, filled in for SeqOnce BioSciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company raising money from the public under Regulation Crowdfunding has to file with the SEC before the offering opens, and has to raise through a single registered intermediary: a funding portal or a broker-dealer. The first filing, Form C, states how much the company is trying to raise, the most it will accept, the deadline, the security and its price, the intermediary and what the intermediary is paid, and two years of the company's own financial figures.
After that the company files amendments when terms change, progress updates as the raise moves, and an annual report each year until it stops reporting. Every row here is one of those filings, linked to the filing itself, so each figure can be checked at the source. Figures are exactly as the company filed them; where a filing leaves a field blank, so does this page. Nothing here is investment advice, and a filing is the company's own statement, not a verification of it.